LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
22 funds hold it · Insiders net selling
Net selling: insiders sold $18.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 5, 2026
Period ending
Sep 30, 2026
Earnings per share
$2.66 expected
Estimates as of Nov 11, 2026
EPS expected
-$0.84 to $1.88
Revenue expected
3 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 5, 2026 | $3.07est. $2.66 | +15.36%beat | $274.4MSEC filing | +5723.6%from $4.7M |
| Jun 30, 2026Reported Aug 5, 2026 | $2.29est. $1.93 | +18.72%beat | $213.5MSEC filing | +3749.2%from $5.5M |
| Mar 31, 2026Reported May 5, 2026 | $0.05est. -$0.65 | +107.64%beat | $56.4MSEC filing | +99.0%from $28.3M |
| Dec 31, 2025Reported Feb 25, 2026 | -$0.69est. -$0.54 | -27.43%miss | $7.4MAlpha Vantage | -95.6%from $170.6M |
| Sep 30, 2025Reported Nov 6, 2025 | -$0.62est. -$0.64 | +3.13%beat | $4.7MSEC filing | +0.8%from $4.7M |
| Jun 30, 2025Reported Aug 6, 2025 | -$0.55est. -$0.52 | -5.77%miss | $5.5MSEC filing | +33.1%from $4.2M |
| Mar 31, 2025Reported May 6, 2025 | -$0.19est. $0.11 | -$0.30miss | $28.3MSEC filing | -88.9%from $255.0M |
| Dec 31, 2024Reported Feb 21, 2025 | $1.98est. $0.25 | +$1.73beat | $170.6MAlpha Vantage | +184.4%from $60.0M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $7.4M | $56.4M | $213.5M | $274.4M |
| Cost of what it sold | $376.0K | $407.0K | — | $1.1M |
| Gross profit | $7.4M | $56.0M | $213.5M | $273.3M |
| What it spent | ||||
| Research and development | $46.4M | $46.7M | $42.1M | $41.3M |
| Sales and admin | $11.4M | $13.3M | $12.6M | $13.7M |
| Total operating expenses | $57.8M | $59.6M | $54.7M | $55.0M |
| What was left | ||||
| Operating profit | -$50.4M | -$3.6M | $158.8M | $218.3M |
| Profit before tax | -$43.7M | $2.3M | $165.1M | $226.6M |
| Tax | $666.0K | -$1.5M | $2.3M | $6.6M |
| Net profit | -$44.4M | $3.8M | $162.8M | $220.0M |
| EBITDA | -$43.3M | $2.7M | $165.5M | $226.6M |
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Protagonist Therapeutics, Inc. $PTGX Stock: Pictet Asset Management Holding SA Lowers Stake
Leans bullishNov 10Wall Street Zen Upgrades Protagonist Therapeutics (NASDAQ:PTGX) to "Strong-Buy"
BullishNov 7A $39.3M year-earlier loss gives way to a Q3 profit at Protagonist Therapeutics (PTGX).
BullishNov 6Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update
BullishNov 5FDA approval of MIMRYLO triggers payments to Protagonist Therapeutics (PTGX).
BullishNov 5Form 8K Protagonist Therapeutics Inc For: 5 November By Investing.com
NeutralNov 5Protagonist Therapeutics (PTGX) Could Be 18% Undervalued As Earnings Expectations Rise
Leans bullishNov 5Polycythemia Vera Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Roche, Fujifilm Holdings Corp, Hangzhou Bensheng Pharma, Protagonist Therape
BullishNov 323 macro signals shaping PTGX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
